Abstract
Collaborations between Emerging and Leading In-vitro Cancer Diagnostics Companies Vital for Greater Market Penetration
With cancer-related deaths in Europe touching one million, there has been a substantial rise in the consumption of resources for diagnosis, treatment and care. Throughout Europe, the five-year survival rate of cancer patients is a mere 30 per cent to 60 per cent. However, in recent times, there has been a reduction in the mortality rate by 10 per cent, which is a gain of 92,000 lives. In this scenario, the in-vitro cancer diagnostics industry is expected to play a vital role in tackling this disease, with encouragement from the collaboration between emerging diagnostic companies and leading participants. Collaborations help the smaller participants with invaluable intellectual property rights, market their tests better.
This Frost & Sullivan research service provides an overview of and outlook for the European in-vitro cancer diagnostics market. The research provides detailed revenue forecasts by end user to help design marketing strategies and maximise growth. The study looks at the vast potential the market holds on account of the range of potential therapeutic approaches available to treat cancer. This enables companies to align their positioning strategies to benefit from the changing markets and obtain maximum return on investments.
Ageing Population Increase Incidence of Cancer, Driving Demand for In-vitro Diagnostics
The European population is slowly ageing, with 17 per cent of the population in almost all the countries being aged 65 years and above. This swelling population segment coupled with the largely unhealthy lifestyle of the Europeans is likely to double the current number of cancer-related cases by 2020, creating robust demand for in-vitro diagnostics. Moreover, the varying survival rates in different European nations strongly indicate that market participants are likely to find immense opportunities in the countries with low cure rates.
"The in-vitro cancer diagnostics market needs to meet the increasing demand for accurate diagnosis, as the concept of personalised medicine is consistently evolving," notes the analyst of this research. "With more numbers of personalised drugs entering the market, it has become important to determine the success rate of a particular treatment on a patient, which, in turn, stresses the need for in-vitro diagnostics."
Newer Drugs and Treatment Methods to Drive the Market
The $523 million in-vitro cancer diagnostics market had grown at 7.0 per cent in 2004 and is projected to expand further to reach $885 million in 2011. This substantial growth is likely to be primarily fuelled by the introduction of more effective drugs and treatment methods, which has, consequently, necessitated greater number of tests for monitoring and therapy selection.
"Governments have also realised the advantages of early screening and detection in cancer diagnostics and have been bringing newer diseases under the purview of national screening programmes," states the analyst. "Due to various government-funded research activities in the field of in-vitro diagnostics, a lot of information on innovative cancer markers has been obtained, building up a strong pipeline of newer tests."
Table of Contents
1 STRATEGIC ANALYSIS OF EUROPEAN IN VITRO CANCER DIAGNOSTICS MARKET
- Overview
- Research Scope and Methodology
- Exchange Rates
Introduction and Segmentation
- Disease Overview
- Common Types Of Cancer
- Disease Prevalence
- Market Segmentation
- Genes Identified with Cancer
Market Overview
- Introduction
- Market Overview
- Market Trends
- Main Applications of Cancer IVDs
- Market Challenges
- Market Drivers
- Proportion of Population Aged Above 65 Years
- Market Restraints
Competitive Landscape
- Market Share Analysis
- Growth/Share Matrix
- Eastern Europe
- Tiers of Competition
- Top Five Companies
Company Profiles
- Key Industry Participants by Product Type
Market Forecasts
- Assumptions
- Total Market Revenue Forecasts
- Revenue Sectoral Analysis
- Immunoassay Based Cancer Diagnostics Revenue Forecasts
- Immunohistochemistry Based Cancer Diagnostics Revenue Forecasts
- Clinical Chemistry Based Cancer Diagnostics Revenue Forecasts
- NAT Based Cancer Diagnostics Revenue Forecast
Strategic Analysis and Recommendations
- Strategic Recommendations
- Key Market Strategies
Latest Technical Developments in Cancer Diagnosis
- Latest Technical Developments
Frost & Sullivan Awards
- Frost & Sullivan Awards
- Entrepreneurial Company Award
- Technology Leadership Award
- Product Line Strategy Award
- Product Differentiation Innovation Award
- Growth Strategy Leadership Award
- Industry Participants
- Decision Support Database
About Frost & Sullivan
- Healthcare Team
- Our Capabilities
